魯妥珠單抗

化合物

魯妥珠單抗INN:lumretuzumab;開發代號:RG7116),或譯魯姆妥珠單抗,是一種人源化HER3單株抗體,設計用於治療癌症[1][2]

魯妥珠單抗
單株抗體
種類完整抗體
目標HER3
臨床資料
其他名稱RG7116
ATC碼
  • 未分配
識別資訊
CAS號1448327-63-6
ChemSpider
  • none
UNII
KEGG
化學資訊
化學式C6512H10064N1736O2052S44
摩爾質量146,916.88 g·mol−1

一項Ib/II期研究調查了在第一線治療晚期或轉移性鱗狀非小細胞肺癌(sqNSCLC)患者時,魯妥珠單抗與卡鉑紫杉醇聯合使用的安全性和臨床活性。[3]

該藥物由基因泰克/羅氏公司開發。

參考資料

編輯
  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lumretuzumab, American Medical Association.
  2. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 (PDF). WHO Drug Information. 2014, 28 (2). 
  3. ^ Cejalvo, Juan-Miguel; Jacob, Wolfgang; Fleitas Kanonnikoff, Tania; Felip, Enriqueta; Navarro Mendivil, Alejandro; Martinez Garcia, Maria; Taus Garcia, Alvaro; Leighl, Natasha; Lassen, Ulrik; Mau-Soerensen, Morten; Adessi, Celine. A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open. 2019, 4 (4). doi:10.1136/esmoopen-2019-000532 (英語).